Budesonide in Severe Alcoholic Hepatitis: Results of the Original Research

Komkova I.I.¹, Tkachenko P.E.^1, , Maevskaya M.V.¹ and Ivashkin V.T.¹

¹Hepatology department, I.M.Sechenov First State Medical University, Moscow, Russia

Cite this paper

Komkova I.I., Tkachenko P.E., Maevskaya M.V. and Ivashkin V.T.. Budesonide in Severe Alcoholic Hepatitis: Results of the Original Research. American Journal of Clinical Medicine Research. 2016; 4(1):7-10. doi: 10.12691/AJCMR-4-1-2

Abstract

Background and aim: Severe alcoholic hepatitis (AH) is a life-threatening alcoholic liver disease with a potential of 30-40% mortality at 1 month. While steroids remain to be a first line therapy, there is a need in alternative treatment. The aim of the study is to compare efficacy and safety of budesonide and prednisolone in treatment of severe AH and to determine predictors of none-response, predictors of short-term mortality. Methods: 37 patients with severe AH were randomized in 2 groups and enrolled in the prospective trial. Group 1 (n=17) patients received budesonide 9 mg/daily per os, group 2 (n=20) patients were managed with prednisolone 40 mg/daily per os. Treatment duration was 28 days. Response criteria – Lille model. Results: There were no significant differences in short-term survival (р = 0,857). In group 2 adverse events were statistically more frequently than in group 1 (70% vs. 26,7%, р = 0,011). Hepatorenal syndrome occurred more frequently in group 2 (р = 0,033). Predictors of non-response were MELD score (р = 0,009), ABIC score (р = 0,011), hepatic encephalopathy (p=0,035), total bilirubin (p=0,016). Predictors of mortality were Lille score (p=0,018), serum glucose (p=0,017), total bilirubin level at the 7th day of the therapy (p=0,030). Conclusions: Budesonide therapy for patients with severe alcoholic hepatitis showed same efficacy as prednisolone treatment with significantly less adverse events. Budesonide appears to be effective in prevention of hepatorenal syndrome.

Keywords

severe alcoholic hepatitis, prednisolone, budesonide, hepatorenal syndrome

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Mayevskaya M.V., Morozova M.A., Ivashkin V.T. Algorithm of management of patient with alcohol-induced liver disease. Russian journal of gastroenterology, hepatology and coloproctology. 2011. Vol. 17 (6), p. 4-10.
[2]	Bueverov A.O., Mayevskaya, M.V., Ivashkin V.T. Differentiated management of alcoholic liver disease.– Russian journal of gastroenterology, hepatology and coloproctology. 2005. Vol. 15 (5), p. 4-10.
[3]	Ivashkin V.T. Gastroenterology: textbook – “Geotar-Media”, 2015.
[4]	Mayevskaya M.V. Alcohol, alcoholism and related consequences. Russian journal of gastroenterology, hepatology and coloproctology. 2013. Vol. 23 (6), p. 43-48.
[5]	Fernández-Checa JC. Alcohol-induced liver disease: when fat and oxidative stress meet. Ann Hepatol. 2003 Apr-Jun; 2 (2): 69-75.
[6]	Limuro Y., Frankenberg M., Arteel G. et al. Female rats exhibit greater susceptibility to early alcohol-induced liver injury than males. Am. J. Physiol. 1997; 272: 1186-1194.
[7]	Naveau S., Cassard-Doulcier A., Njiké-Nakseu M., Bouchet-Delbos L., Barri-Ova N., Boujedidi H., Dauvois B. et. al. Harmful effect of adipose tissue on liver lesions in patients with alcoholic liver disease. J Hepatol. 2010 Jun; 52 (6): 895-902. Epub 2010 Mar 24.
[8]	Mathurin P. Therapeutic management of alcoholic hepatitis. Clinical Research in Hepatology and Gastroenterology. 2015 Jul; 39: 41-45.
[9]	O’Shea R.S., Dasarathy S., McCullough A.J. et al. Alcoholic liver disease. AASLD practice guidelines. Hepatology. 2010; 51(1): 307-328.
[10]	Sheth M, Riggs M, Patel T. Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol. 2002; 2: 2.
[11]	Mayevskaya M.V., Morozova M.A., Ivashkin V.T. Management of patients with alcoholic liver disease. - Russian journal of gastroenterology, hepatology and coloproctology. 2007; 17(6): 1-10.
[12]	P. Maturin, M.R. Lucey. Management of alcoholic hepatitis. Journal of Hepatology. 2012; 56, supplement 1: 39-45.
[13]	Manns MP, Woynarowski M, Kreisel W, Lurie Y, Rust C, Zuckerman E, Bahr MJ et. al. European AIH-BUC-Study Group Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010 Oct; 139(4): 1198-206. Epub 2010 Jun 22.
[14]	Zandieh I, Krygier D, Wong V, Howard J, Worobetz L, Minuk G, Witt-Sullivan H et. al. The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can J Gastroenterol. 2008 Apr; 22(4): 388-92.
[15]	Czaja AJ. Autoimmune hepatitis: Focusing on treatments other than steroids. Can J Gastroenterol. 2012 Sep; 26(9): 615-20.
[16]	D'Haens GR, Kovács A, Vergauwe P, Nagy F, Molnár T, Bouhnik Y, Weiss W et. al. Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis. J Crohns Colitis. 2010 Jun; 4(2): 153-60. Epub 2009 Oct 24.
[17]	Seow CH, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2008 Jul 16; (3).
[18]	Wagner M, Lampinen M, Sangfelt P, Agnarsdottir M, Carlson M. Budesonide treatment of patients with collagenous colitis restores normal eosinophil and T-cell activity in the colon. Inflamm Bowel Dis. 2010 Jul; 16(7): 1118-26.
[19]	Bush KR, Bradley KA, McDonell MB, Malone T, Fihn SD; Screening for problem drinking: Comparison of CAGE and AUDIT. Ambulatory Care Quality Improvement Project. J Gen Intern Med. 1998 Jun; 13 (6): 379-88.
[20]	Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, Mathurin P. et. al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007 Jun; 45 (6): 1348-54.
[21]	Hempfling W., Grunhage F., Dilger K., Reichel C, Beuers U., Sauerbruch T. Pharmacokinetics and Pharmacodynamic Action of Budesonide in Early- and Late-Stage Primary Biliary Cirrhosis. Hepatology. 2003 Jul; 38 (1): 196-202.
[22]	Efe C., Ozaslan E., Kav T. Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome. Autoimmunity Reviews 11 (2012): 330-33.
[23]	Mederacke I., Helfritz F., Puls F. Budd-Chiary syndrome after treatment with budesonide in a cirrhotic patient with autoimmune hepatitis. Annals of Hepatology. 2012; 11(1), p 143-144.